✦ LIBER ✦

82 Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): Interim results of a randomised controlled trial

✍ Scribed by P. Ferenci; H. Brunner; H. Laferl; U. Bergholz; M. Rosenbeiger; R. Stauber; A. Maieron; G. Fischer; M. Bischof; P. Steindl-Munda

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.411 The impact of age on sustained vir

✍ J. Rockstroh; F.J. Torriani; M. Rodriguez Torres; E. Lissen; A. Lazzarin; J. De 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 274 KB

566 Pharmacokinetics and pharmacodynamic

✍ M. Diago; M. Romero-Gomez; J. Crespo; A. Olveira; R. Perez; R. Barcena; J.M. San 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 265 KB

734 Peginterferon alpha-2a (PEGASYS) plu

✍ M.L. Shiffman; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacons; J. Rase 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 124 KB

987 Peginterferon alfa-2A (40KD) (PEGASY

✍ HERNANDEZQUERO, J; PEREZGUZMAN, E; LOZANO, F; PARRA, J; DELMARALONSO, M 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB

O.160 16 or 24 weeks of peginterferon al

✍ S. Zeuzem; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacon; E. Godofsky; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 143 KB

567 Peginterferon alpha-2a (40KD) (PEGAS

✍ M. Diago; R. Sola; A. Olveira; M. Romero-Gomez; R. Planas; R. Moreno; R. Perez; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 134 KB